## First－half 2011 results

## HISTORICALLY HIGH NET PROFIT＊： 1，506 MILLION EUROS

＞Solid and good quality results：
－Improvement in gross profit at $71.5 \%$
－Sustained investments in R\＆D and Advertising \＆Promotion
－High operating margin，at $16.8 \%$ of sales
－Net profit excluding non－recurring items after non－controlling interests： €1，506m，＋6．7\％
－Net profit after non－controlling interests：＋11．6\％
－EPS＊＊at 2.52 euros：$+5.4 \%$

## Confidence in the improvement of profitability for 2011.

Commenting on the figures，Mr Jean－Paul Agon，Chairman and CEO of L＇Oréal，said：
＂Organic growth in the first half of 2011 has confirmed the good dynamics of the group，which is further strengthening its worldwide positions，particularly in North America，in Latin America and in Asia Pacific．

The first－half results are up，solid and of good quality．Gross profit is improving，despite the higher cost of raw materials．Operating margin is at a high level，and net profit is growing strongly．At the same time we are continuing to pave the way for the future with our ongoing policy of sustained investments in R\＆D and advertising \＆promotion business drivers．Finally，the group＇s debt is particularly low．

These performances reflect the quality and solidity of the L＇Oréal business model，based on powerful innovation，the vitality of our brand portfolio and a vast potential for internationalisation． In an uncertain economic environment，these fundamentals make us more confident than ever in the group＇s ability to build sustainable and profitable growth．

For 2011，we confirm our ambition to outperform the market and improve the group＇s profitability．＂

[^0]
## A - First-half 2011 sales

- Based on reported figures, the group's sales, at June $30^{\text {th }}$, 2011, amounted to 10.15 billion euros, an increase of $+5.0 \%$. Like-for-like, i.e. based on a comparable structure and identical exchange rates, the sales growth of the L'Oréal group was $+5.2 \%$. The net impact of changes in consolidation was $+0.7 \%$. Currency fluctuations had a negative impact of $-0.9 \%$. Growth at constant exchange rates was $+5.9 \%$.
- If the exchange rates at the end of July, i.e. $€ 1=\$ 1.438$, are extrapolated up to December $31^{\text {st }}$, the impact of currency fluctuations on sales would be approximately $-1.8 \%$ for the whole of 2011.
- The news release of July $12^{\text {th }}, 2011$ details the activity for the first half of 2011 . This news release is available and can be downloaded from the www.loreal-finance.com website.

Sales by operational division and geographic zone

|  | $2^{\text {nd }}$ quarter 2011 |  |  | $1^{\text {st }}$ half 2011 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | €m | Growth |  | €m | Growth |  |
|  |  | Like-for-like | Reported |  | Like-for-like | Reported |
| By operational division |  |  |  |  |  |  |
| Professional Products | 704.6 | 1.2\% | -0.7\% | 1,420.2 | 2.1\% | 4.2\% |
| Consumer Products | 2,453.6 | 4.0\% | -0.2\% | 5,037.3 | 5.2\% | 4.5\% |
| Luxury Products | 1,133.3 | 9.5\% | 3.8\% | 2,249.8 | 8.5\% | 6.9\% |
| Active Cosmetics | 352.6 | 1.2\% | -0.9\% | 797.7 | 3.2\% | 3.2\% |
| Cosmetics total | 4,644.0 | 4.6\% | 0.6\% | 9,505.0 | 5.3\% | 4.9\% |
| By geographic zone |  |  |  |  |  |  |
| Western Europe | 1,854.9 | 1.2\% | 1.4\% | 3,765.3 | 0.8\% | 1.4\% |
| North America | 1,066.2 | 4.5\% | -4.9\% | 2,183.4 | 5.8\% | 3.1\% |
| New Markets, of which: | 1,722.9 | 8.6\% | 3.4\% | 3,556.3 | 10.1\% | 10.1\% |
| - Asia Pacific | 831.2 | 14.4\% | 8.1\% | 1,748.1 | 13.0\% | 13.5\% |
| - Eastern Europe | 325.3 | -5.4\% | -8.2\% | 680.0 | -3.4\% | -3.8\% |
| - Latin America | 427.1 | 11.7\% | 7.5\% | 830.7 | 17.3\% | 18.0\% |
| - Africa, Middle East | 139.4 | 4.3\% | -4.6\% | 297.6 | 10.1\% | 6.4\% |
| Cosmetics total | 4,644.0 | 4.6\% | 0.6\% | 9,505.0 | 5.3\% | 4.9\% |
| The Body Shop | 167.9 | 4.5\% | -1.3\% | 337.4 | 2.6\% | 0.9\% |
| Dermatology ${ }^{(1)}$ | 177.5 | 4.9\% | 12.2\% | 307.2 | 5.3\% | 13.6\% |
| Group total | 4,989.4 | 4.6\% | 0.9\% | 10,149.6 | 5.2\% | 5.0\% |

[^1]
## B - First-half 2011: Solid and good quality results

The half-year consolidated accounts have undergone a limited examination by the Statutory Auditors.

## 1) Operating profitability at $\mathbf{1 6 . 8 \%}$ of sales

Consolidated profit and loss accounts: from sales to operating profit.

| In $\boldsymbol{€} \boldsymbol{m}$ | 06/30/10 | As \% of sales | 12/31/10 | As \% of sales | 06/30/11 | As \% of sales | $\begin{gathered} \hline \text { Growth } \\ 06 / 30 / 10 \\ 06 / 30 / 11 \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | 9,667 | 100\% | 19,496 | 100\% | 10,150 | 100\% | + 5.0\% |
| Cost of sales | -2,776 | 28.7\% | -5,697 | 29.2\% | -2,890 | 28.5\% | +4.1\% |
| Gross Profit | 6,890 | 71.3\% | 13,799 | 70.8\% | 7,260 | 71.5\% | +5.4\% |
| R\&D expenses | -309 | 3.2\% | -665 | 3.4\% | -346 | 3.4\% | +12.2\% |
| Advertising and promotion expenses | -2,950 | 30.5\% | -6,029 | 30.9\% | -3,135 | 30.9\% | +6.3\% |
| Selling, general and administrative expenses | -1,963 | 20.3\% | -4,049 | 20.8\% | -2,076 | 20.5\% | +5.8\% |
| Operating profit | 1,669 | 17.3\% | 3,057 | 15.7\% | 1,702 | 16.8\% | +2.0\% |

Gross profit, at $€ 7,260 \mathrm{~m}$, increased by $5.4 \%$, and came out at $71.5 \%$ of sales, compared with $71.3 \%$ in the first half of 2010. Despite the unfavourable impact of higher raw materials prices, the improved efficiency and productivity of the factories, good stock management and finally the positive conversion effect, resulting from the strengthening of the euro, have contributed to this further improvement.

Research and development expenses have increased by $12.2 \%$. This increase reflects the group's determination to step up its investments in Research and Innovation and, to a lesser extent, the integration of Q-Med.
Advertising and promotion expenses came out at $30.9 \%$ of sales, amounting to $€ 3,135 \mathrm{~m}$, in line with the level for the full-year 2010.
Selling, general and administrative expenses amounted to $€ 2,076 \mathrm{~m}$, representing $20.5 \%$ of sales, a level below that recorded in the full-year 2010.

Operating profit, at $16.8 \%$ of sales, amounted to $€ 1,702 \mathrm{~m}$. This compares with the record level achieved in the first half of 2010 of $17.3 \%$. The difference compared with the first half of 2010 , that is 50 basis points, is the result of increased investments in R\&D and advertising \& promotion business drivers.


## 2) Operating profit by branch and division

|  | 06/30/10 |  | 12/31/10 |  | 06/30/11 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | €m | \% of sales | €m | \% of sales | €m | \% of sales |
| By operational division |  |  |  |  |  |  |
| Professional Products | 288 | 21.2\% | 552 | 20.3\% | 281 | 19.8\% |
| Consumer Products | 982 | 20.4\% | 1,765 | 18.5\% | 1,013 | 20.1\% |
| Luxury Products | 378 | 18.0\% | 791 | 17.5\% | 426 | 18.9\% |
| Active Cosmetics | 208 | 26.9\% | 278 | 20.1\% | 210 | 26.3\% |
| Cosmetics divisions total | 1,856 | 20.5\% | 3,385 | 18.7\% | 1,930 | 20.3\% |
| Non-allocated* | -235 | -2.6\% | -513 | -2.8\% | -262 | -2.8\% |
| Cosmetics branch total | 1,622 | 17.9\% | 2,872 | 15.8\% | 1,668 | 17.5\% |
| The Body Shop | 14 | 4.1\% | 65 | 8.7\% | 9 | 2.8\% |
| Dermatology branch** | 33 | 12.4\% | 119 | 19.8\% | 25 | 8.1\% |
| Group | 1,669 | 17.3\% | 3,057 | 15.7\% | 1,702 | 16.8\% |

[^2]The Professional Products Division is operating in a difficult market this year, and its profitability has edged down from 21.2\% to 19.8\%.
The profitability of the Consumer Products Division at $20.1 \%$ is slightly down on the first half of 2010, but is considerably higher than the full-year 2010 figure of $18.5 \%$.
The profitability of the Luxury Products Division, at 18.9\%, has grown strongly.
The Active Cosmetics Division has again recorded very high profitability at 26.3\%.
The increase in non-allocated costs, at 2.8\%, is mainly the result of the rise in Research expenses.
The profitability of The Body Shop, which is mainly achieved in the second half of each year, came out at 2.8\%.

The decline in profitability of Dermatology is the result of two factors: firstly, competition from generics for Differin $0.1 \%$ gel and cream and for Loceryl and, secondly, negative exchange rate effects.
3) Net earnings per share*: $€ 2.52$

Consolidated profit and loss accounts, from operating profit to net profit excluding non-recurring items.

| In $€ \boldsymbol{m}$ | 06/30/10 | 12/31/10 | 06/30/11 | $\begin{gathered} \text { Evolution } \\ 06 / 30 / 10 \\ 06 / 30 / 11 \\ \hline \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: |
| Operating profit | 1,669 | 3,057 | 1,702 | +2.0\% |
| Financial revenues and expenses excluding dividends received | -18 | -36 | -9 |  |
| Sanofi dividends | 284 | 284 | 296 |  |
| Profit before tax excluding non-recurring items | 1,935 | 3,305 | 1,989 | +2.8\% |
| Income tax excluding non-recurring items | -522 | -932 | -481 |  |
| Non-controlling interests | -2 | -2 | -2 |  |
| Net profit excluding non-recurring items after noncontrolling interests | 1,411 | 2,371 | 1,506 | +6.7\% |
| Net EPS ** ( $¢$ ) | 2.39 | 4.01 | 2.52 | +5.4\% |
| Net profit after non-controlling interests | 1,314 | 2,240 | 1,467 |  |
| Diluted net EPS after non-controlling interests (€) | 2.23 | 3.79 | 2.46 |  |
| Diluted average number of shares | 589,549,689 | 591,392,449 | 596,970,041 |  |

* Net profit excluding non-recurring items after non-controlling interests does not include capital gains and losses on disposals of longterm assets, impairment of assets, restructuring costs, as well as competition litigation, and associated tax effects or non-controlling interests.
** Diluted net earnings per share excluding non-recurring items after non-controlling interests.
Overall finance costs, at $€ 9 m$, have fallen sharply compared with the first half of 2010. This large reduction is the result of the significant decline in net debt.
The dividend received from Sanofi for 2010 amounted to $€ 296 m$, an increase of $+4.2 \%$.
Profit before tax excluding non-recurring items amounted to $€ 1,989 \mathrm{~m}$, an increase of $+2.8 \%$.
Income tax amounted to $€ 481 \mathrm{~m}$, less than in the first half of 2010.

Net profit excluding non-recurring items after non-controlling interests amounted to $€ 1,506 \mathrm{~m}$, up by $+6.7 \%$. EPS amounted to $€ 2.52$, up by +5.4\% compared with the first half of 2010.

After allowing for non-recurring items, net profit after non-controlling interests amounted to $€ 1,467 \mathrm{~m}$, an increase of $\mathbf{+ 1 1 . 6 \%}$.

## 4) Stable operating cash flow and a robust balance sheet

Gross cash flow amounted to $€ 1,795 \mathrm{~m}$, which is stable compared with the first half of 2010.
The change in working capital has increased by $€ 701 \mathrm{~m}$. The greater increase compared with the first half of 2010 stems mainly from the trade accounts payable and tax items.
Total cash flows from operating activities (see cash flow statement in Appendix VI ) amounted to €1,094m.
Investments amounted to $€ \mathbf{4 0 0} \mathbf{m}$ that is approximately $4 \%$ of sales.
At June $30^{\text {th }}, 2011$, net financial debt totalled $€ \mathbf{5 2 6}$. Gearing amounted to $3.3 \%$ of shareholders' equity.

The balance sheet structure, which was already robust, was further reinforced with shareholders' equity representing 64\% of total assets.

[^3]Contacts at L'ORÉAL (Switchboard: +33 1475670 00)

Individual shareholders
and market authorities
Mr Jean Régis CAROF
Tel: +33 147568302 icarof@dgaf.loreal.com

Financial analysts and Institutional investors

Mrs Françoise LAUVIN
Tel: +33 147568682 flauvin@dgaf.loreal.com

## Journalists

Mrs Stephanie CARSON-PARKER
Tel: +33 147567671 scarsonparker@dgc.loreal.com

For more information, please contact your bank, broker or financial institution (I.S.I.N. code: FR0000120321), and consult your usual newspapers, and the Internet site for shareholders and investors, http://www.loreal-finance.com, or its mobile version on your cell phone, http://loreal-finance.mobi; alternatively, call +33140148050

## C - Appendices

## I-Consolidated profit and loss accounts

| $€$ millions | $1^{\text {st }}$ half 2011 | $1^{\text {st }}$ half 2010 | 2010 |
| :---: | :---: | :---: | :---: |
| Net sales | 10,149.6 | 9,666.8 | 19,495.8 |
| Cost of sales | -2,889.5 | -2,776.3 | -5,696.5 |
| Gross profit | 7,260.1 | 6,890.4 | 13,799.3 |
| Research and development | -346.3 | -308.7 | -664.7 |
| Advertising and promotion | -3,135.4 | -2,950.4 | -6,029.1 |
| Selling, general and administrative expenses | -2,076.1 | -1,962.8 | $-4,048.6$ |
| Operating profit | 1,702.3 | 1,668.6 | 3,056.9 |
| Other income and expenses | -62.6 | -107.0 | -153.2 |
| Operational profit | 1,639.7 | 1,561.5 | 2,903.7 |
| Finance costs on gross debt | -18.8 | -23.5 | -43.8 |
| Finance income on cash and cash equivalents | 12.7 | 9.2 | 17.2 |
| Finance costs, net | -6.1 | -14.3 | -26.6 |
| Other financial income (expenses) | -3.2 | -3.5 | -9.0 |
| Sanofi dividends | 295.6 | 283.8 | 283.8 |
| Profit before tax and non-controlling interests | 1,926.0 | 1,827.5 | 3,151.9 |
| Income tax | -457.9 | -511.5 | -909.9 |
| Net profit | 1,468.1 | 1,316.0 | 2,242.0 |
| attributable to: |  |  |  |
| - owners of the company | 1,466.6 | 1,314.3 | 2,239.7 |
| - non-controlling interests | 1.5 | 1.7 | 2.3 |
| Earnings per share attributable to owners of the company (euros) | 2.48 | 2.24 | 3.82 |
| Diluted earnings per share attributable to owners of the company (euros) | 2.46 | 2.23 | 3.79 |
| Earnings per share attributable to owners of the company excluding nonrecurring items (euros) | 2.55 | 2.41 | 4.04 |
| Diluted earnings per share attributable to owners of the company excluding non-recurring items (euros) | 2.52 | 2.39 | 4.01 |

## II - Consolidated statements of net profit and gains and losses directly recognised in equity

| $\neq$ millions | $\mathbf{1}^{\text {st }}$ half $\mathbf{2 0 1 1}$ | $\mathbf{1}^{\text {st }}$ half $\mathbf{2 0 1 0}$ | $\mathbf{2 0 1 0}$ |
| :--- | ---: | ---: | ---: |
| Consolidated net profit for the period | $\mathbf{1 , 4 6 8 . 1}$ | $\mathbf{1 , 3 1 6 . 0}$ | $\mathbf{2 , 2 4 2 . 0}$ |
| Financial assets available for sale | 896.7 | -653.8 | -852.3 |
| Cash flow hedges | 37.7 | -81.0 | -8.0 |
| Actuarial gains and losses | -1.0 | -0.4 | -213.5 |
| Tax effect on items directly recognised in equity ${ }^{(1)}$ | -25.8 | 32.8 | 92.0 |
| Cumulative translation adjustments | -359.5 | 798.4 | 463.3 |
| Changes in gains and losses directly recognised in equity | $\mathbf{5 4 8 . 1}$ | $\mathbf{9 6 . 0}$ | $\mathbf{- 5 1 8 . 5}$ |
| Total net profit and gains and losses directly recognised in equity | $\mathbf{2 , 0 1 6 . 2}$ | $\mathbf{1 , 4 1 2 . 0}$ | $\mathbf{1 , 7 2 3 . 5}$ |
| Attributable to: |  |  |  |
| - owners of the company | $\mathbf{2 , 0 1 4 . 6}$ | $\mathbf{1 , 4 1 0 . 3}$ | $\mathbf{1 , 7 2 1 . 2}$ |
| - non-controlling interests | 1.6 | 1.7 | 2.3 |

[^4]| € millions | $\mathbf{1}^{\text {st }}$ half $\mathbf{2 0 1 1}$ | $\mathbf{1}^{\text {st }}$ half $\mathbf{2 0 1 0}$ | $\mathbf{2 0 1 0}$ |
| :--- | ---: | ---: | ---: |
| Financial assets available for sale | -15.2 | 11.3 | $\mathbf{1 4 . 6}$ |
| Cash flow hedges | -10.8 | 21.3 | 1.1 |
| Actuarial gains and losses | 0.2 | 0.2 | 76.3 |
| Total | $\mathbf{- 2 5 . 8}$ | $\mathbf{3 2 . 8}$ | $\mathbf{9 2 . 0}$ |

## III - Consolidated balance sheets

Assets

| $€$ millions | $\mathbf{0 6 . 3 0 . 2 0 1 1}$ | $\mathbf{0 6 . 3 0 . 2 0 1 0}$ | $\mathbf{1 2 . 3 1 . 2 0 1 0}$ |
| :--- | ---: | ---: | ---: |
| Non-current assets | $\mathbf{1 7 , 9 4 5 . 8}$ | $\mathbf{1 7 , 6 0 5 . 6}$ |  |
| Goodwill | $5,705.9$ | $5,894.9$ | $\mathbf{1 7 , 0 4 8 . 2}$ |
| Other intangible assets | $2,232.0$ | $2,297.0$ | $2,177.5$ |
| Tangible assets | $2,672.0$ | $2,780.0$ | $2,677.5$ |
| Non-current financial assets | $6,729.0$ | $6,043.9$ | $5,837.5$ |
| Deferred tax assets | 606.9 | 589.8 | 626.1 |
| Current assets | $\mathbf{7 , 2 3 0 . 2}$ | $\mathbf{7 , 1 6 0 . 0}$ | $\mathbf{6 , 9 9 6 . 3}$ |
| Inventories | $1,896.0$ | $1,766.6$ | $\mathbf{1 , 8 1 0 . 1}$ |
| Trade accounts receivable | $3,049.9$ | $3,077.5$ | $2,685.3$ |
| Other current assets | 969.9 | 833.8 | 846.0 |
| Current tax assets | 60.0 | 48.1 | 104.5 |
| Cash and cash equivalents | $\mathbf{1 , 2 5 4 . 4}$ | $1,434.0$ | $1,550.4$ |
| Total | $\mathbf{2 5 , 1 7 6 . 0}$ | $\mathbf{2 4 , 7 6 5 . 6}$ | $\mathbf{2 4 , 0 4 4 . 5}$ |

## Equity \& Liabilities

| $€$ millions | 06.30.2011 | 06.30.2010 | 12.31.2010 |
| :---: | :---: | :---: | :---: |
| Equity | 16,118.3 | 14,254.3 | 14,865.8 |
| Share capital | 120.5 | 119.9 | 120.2 |
| Additional paid-in capital | 1,251.2 | 1,053.9 | 1,148.3 |
| Other reserves | 12,322.5 | 11,052.9 | 11,107.1 |
| Items directly recognised in equity | 2,095.6 | 1,467.6 | 1,188.1 |
| Cumulative translation adjustments | -449.1 | 245.4 | -89.6 |
| Treasury stock | -691.3 | -1,002.5 | -850.9 |
| Net profit attributable to owners of the company | 1,466.6 | 1,314.3 | 2,239.7 |
| Equity attributable to owners of the company | 16,116.0 | 14,251.5 | 14,862.9 |
| Non-controlling interests | 2.3 | 2.8 | 2.9 |
| Non-current liabilities | 1,854.5 | 2,593.5 | 2,596.6 |
| Provisions for employee retirement and obligations and related benefits | 1,012.0 | 1,006.4 | 1,129.0 |
| Provisions for liabilities and charges | 172.6 | 163.2 | 181.3 |
| Deferred tax liabilities | 506.1 | 429.4 | 462.0 |
| Non-current borrowings and debt | 163.8 | 994.5 | 824.3 |
| Current liabilities | 7,203.2 | 7,917.8 | 6,582.1 |
| Trade accounts payable | 2,997.3 | 2,950.1 | 3,153.5 |
| Provisions for liabilities and charges | 517.0 | 602.8 | 536.9 |
| Other current liabilities | 1,905.8 | 2,039.2 | 1,958.1 |
| Income tax | 166.4 | 213.4 | 166.6 |
| Current borrowings and debt | 1,616.7 | 2,112.3 | 767.0 |
| Total | 25,176.0 | 24,765.6 | 24,044.5 |

## IV - Consolidated statements of changes in equity

| € millions | Common shares outstanding | Share capital | Additional paid-in capital | Retained earnings and net profit | Items directly recognised in equity | Treasury stock | Cumulative translation adjustments | Equity attributable to owners of the company | $\begin{array}{r} \text { Non- } \\ \text { controlling } \\ \text { interests } \\ \hline \end{array}$ | Total equity |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| At 12.31.2009 | 584,735,660 | 119.8 | 996.5 | 11,933.5 | 2,169.9 | -1,071.6 | -552.9 | 13,595.2 | 3.1 | 13,598.3 |
| Consolidated net profit for the period |  |  |  | 2,239.7 |  |  |  | 2,239.7 | 2.3 | 2,242.0 |
| Financial assets available for sale |  |  |  |  | -837.7 |  |  | -837.7 |  | -837.7 |
| Cash flow hedges |  |  |  |  | -6.8 |  |  | -6.8 |  | -6.8 |
| Actuarial gains and losses |  |  |  |  | -137.3 |  |  | -137.3 |  | -137.3 |
| Cumulative translation adjustments |  |  |  |  |  |  | 463.3 | 463.3 |  | 463.3 |
| Change in gains and losses directly recognised in equity |  |  |  |  | -981.8 |  | 463.3 | -518.5 | - | -518.5 |
| Total net profit and gains and losses directly recognised in equity |  |  |  | 2,239.7 | -981.8 |  | 463.3 | 1,721.2 | 2.3 | 1,723.5 |
| Capital increase | 2,520,175 | 0.5 | 151.8 |  |  |  |  | 152.3 |  | 152.3 |
| Cancellation of treasury stock |  | -0.1 |  | -37.8 |  | 37.9 |  | - |  | - |
| Dividends paid (not paid on treasury stock) |  |  |  | -878.8 |  |  |  | -878.8 | -2.2 | -881.0 |
| Share-based payment |  |  |  | 84.8 |  |  |  | 84.8 |  | 84.8 |
| Net changes in treasury stock | 2,400,068 |  |  | 1.1 |  | 182.8 |  | 183.9 |  | 183.9 |
| Purchase of non-controlling interests |  |  |  | -2.9 |  |  |  | -2.9 |  | -2.9 |
| Other movements |  |  |  | 7.2 |  |  |  | 7.2 | -0.3 | 6.9 |
| At 12.31.2010 | 589,655,903 | 120.2 | 1,148.3 | 13,346.8 | 1,188.1 | -850.9 | -89.6 | 14,862.9 | 2.9 | 14,865.8 |
| Consolidated net profit for the period |  |  |  | 1,466.6 |  |  |  | 1,466.6 | 1.5 | 1,468.1 |
| Financial assets available for sale |  |  |  |  | 881.5 |  |  | 881.5 |  | 881.5 |
| Cash flow hedges |  |  |  |  | 26.8 |  |  | 26.8 | 0.1 | 26.9 |
| Actuarial gains and losses |  |  |  |  | -0.8 |  |  | -0.8 |  | -0.8 |
| Cumulative translation adjustments |  |  |  |  |  |  | -359.5 | -359.5 |  | -359.5 |
| Change in gains and losses directly recognised in equity |  |  |  |  | 907.5 |  | -359.5 | 548.0 | 0.1 | 548.1 |
| Total net profit and gains and losses directly recognised in equity |  |  |  | 1,466.6 | 907.5 |  | -359.5 | 2,014.6 | 1.6 | 2,016.2 |
| Capital increase | 1,661,947 | 0.3 | 102.9 |  |  |  |  | 103.2 |  | 103.2 |
| Cancellation of treasury stock |  |  |  |  |  |  |  | - |  | - |
| Dividends paid (not paid on treasury stock) |  |  |  | -1,065.3 |  |  |  | -1,065.3 | -1.9 | -1,067.2 |
| Share-based payment |  |  |  | 39.0 |  |  |  | 39.0 |  | 39.0 |
| Net changes in treasury stock | 2,106,656 |  |  | 1.3 |  | 159.6 |  | 160.9 |  | 160.9 |
| Purchase of non-controlling interests |  |  |  |  |  |  |  | - |  | - |
| Other movements |  |  |  | 0.7 |  |  |  | 0.7 | -0.3 | 0.4 |
| At 06.30.2011 | 593,424,506 | 120.5 | 1,251.2 | 13,789.1 | 2,095.6 | -691.3 | -449.1 | 16,116.0 | 2.3 | 16,118.3 |

## V - Changes in first half 2010

| € millions | Common shares outstanding | Share capital | Additional paid-in capital | Retained earnings and net profit | Items directly recognised in equity | Treasury stock | Cumulative translation adjustments | Equity attributable to owners of the company | Noncontrolling interests | Total equity |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| At 12.31.2009 | 584,735,660 | 119.8 | 996.5 | 11,933.5 | 2,169.9 | -1,071.6 | -552.9 | 13,595.2 | 3.1 | 13,598.3 |
| Consolidated net profit for the period |  |  |  | 1,314.3 |  |  |  | 1,314.3 | 1.7 | 1,316.0 |
| Financial assets available for sale |  |  |  |  | -642.5 |  |  | -642.5 |  | -642.5 |
| Cash flow hedges |  |  |  |  | -59.6 |  |  | -59.6 | -0.1 | -59.7 |
| Actuarial gains and losses |  |  |  |  | -0.2 |  |  | -0.2 |  | -0.2 |
| Cumulative translation adjustments |  |  |  |  |  |  | 798.3 | 798.3 | 0.1 | 798.4 |
| Change in gains and losses directly recognised in equity |  |  |  |  | -702.3 |  | 798.3 | 96.0 | - | 96.0 |
| Total net profit and gains and losses directly recognised in equity |  |  |  | 1,314.3 | -702.3 |  | 798.3 | 1,410.3 | 1.7 | 1,412.0 |
| Capital increase | 959,950 | 0.2 | 57.4 |  |  |  |  | 57.6 |  | 57.6 |
| Cancellation of treasury stock |  | -0.1 |  | -37.8 |  | 37.9 |  | - |  | - |
| Dividends paid (not paid on treasury stock) |  |  |  | -878.8 |  |  |  | -878.8 | -2.0 | -880.8 |
| Share-based payment |  |  |  | 38.7 |  |  |  | 38.7 |  | 38.7 |
| Net changes in treasury stock | 460,700 |  |  | 0.4 |  | 31.2 |  | 31.6 |  | 31.6 |
| Purchase of non-controlling interests |  |  |  | -3.1 |  |  |  | -3.1 |  | -3.1 |
| Other movements |  |  |  |  |  |  |  | - |  | - |
| At 06.30.2010 | 586,156,310 | 119.9 | 1,053.9 | 12,367.2 | 1,467.6 | -1,002.5 | 245.4 | 14,251.5 | 2.8 | 14,254.3 |

## VI - Consolidated statements of cash flows

| $€$ millions | $1^{\text {st }}$ half 2011 | $\mathbf{1}^{\text {st }}$ half 2010 | 2010 |
| :---: | :---: | :---: | :---: |
| Cash flows from operating activities |  |  |  |
| Net profit attributable to owners of the company | 1,466.6 | 1,314.3 | 2,239.7 |
| Non-controlling interests | 1.5 | 1.7 | 2.3 |
| Elimination of expenses and income with no impact on cash flows: |  |  |  |
| - depreciation, amortisation and provisions | 276.7 | 398.6 | 734.2 |
| - changes in deferred taxes | 14.2 | 39.4 | 110.0 |
| - share-based payment | 39.0 | 38.7 | 84.8 |
| - capital gains and losses on disposals of assets | -3.1 | -0.4 | 0.1 |
| Gross cash flow | 1,795.0 | 1,792.3 | 3,171.1 |
| Changes in working capital | -701.1 | -289.2 | 132.5 |
| Net cash provided by operating activities (A) | 1,093.9 | 1,503.1 | 3,303.6 |
| Cash flows from investing activities |  |  |  |
| Investments in tangible and intangible assets | -400.2 | -320.9 | -677.9 |
| Disposal of tangible and intangible assets | 7.1 | 6.0 | 18.3 |
| Changes in other financial assets (including investments in non-consolidated companies) | -3.9 | 11.7 | 2.3 |
| Effect of changes in the scope of consolidation | -330.9 | -124.3 | -160.7 |
| Net cash (used in) from investing activities (B) | -727.9 | -427.5 | -818.0 |
| Cash flows from financing activities |  |  |  |
| Dividends paid | -1,096.8 | -896.4 | -921.6 |
| Capital increase of the Parent Company | 103.2 | 57.6 | 152.3 |
| Disposal (acquisition) of treasury stock | 160.9 | 31.6 | 184.0 |
| Purchase of non-controlling interests | - | -8.4 | -8.7 |
| Issuance (repayment) of short-term loans | 628.2 | -9.6 | -132.6 |
| Issuance of long-term borrowings | - | - | 4.0 |
| Repayment of long-term borrowings | -411.0 | -101.6 | -1,462.5 |
| Net cash (used in) from financing activities (C) | -615.4 | -926.8 | -2,185.1 |
| Net effect of changes in exchange rates and fair value (D) | -46.6 | 112.1 | 76.9 |
| Change in cash and cash equivalents ( $A+B+C+D$ ) | -296.0 | 260.9 | 377.4 |
| Cash and cash equivalents at beginning of the year (E) | 1,550.4 | 1,173.1 | 1,173.1 |
| Cash and cash equivalents at end of the period (A+B+C+D+E) | 1,254.4 | 1,434.0 | 1,550.4 |


[^0]:    ＊net profit excluding non－recurring items after non－controlling interests．
    ＊＊diluted net earnings per share，based on net profit excluding non－recurring items after non－controlling interests．

[^1]:    ${ }^{(1)}$ Group share, i.e. $50 \%$.

[^2]:    *Non-allocated = Central group expenses, fundamental research expenses, stock option and free grant of shares expenses and miscellaneous items. As \% of cosmetics sales.
    ** Group share, i.e. $50 \%$.

[^3]:    "This news release does not constitute an offer to sell, or a solicitation of an offer to buy L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers, also available in English on our Internet site www.loreal-finance.com.
    This news release may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements."

[^4]:    (1) The tax effect is as follows:

